medigraphic.com
ISSN 1561-2988 (Print)

2014, Number 4

Next >>

Rev Cubana Farm 2014; 48 (4)

Drugs or goods

Debesa GF

Language: Spanish
References: 15
Page: 529-532
PDF size: 43.98 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Flower R. Lifestyle drugs: pharmacology and the social agenda. Trends Pharmacol Sci. 2004;25:182-5.

  2. Ilich I. Némesis médica. México DF: Ediciones Joaquín Mortiz; 1976.

  3. Payer L. Disease-mongers: how doctors, drug companies, and insurers are making you feel sick. Nueva York: John Wiley & Sons; 1992.

  4. Ruiz-Cantero MT. Marketing farmacéutico. Fronterad 2010. [citado 5 Sept 2014]. Available from: http://www.fronterad.com/?q=marketing-farmaceutico

  5. Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Med. 2010 [cited 2014 Oct 5];7:e1000352. Available from: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed. 1000352

  6. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ. 2002;324:886-91.

  7. Moynihan R, Mintzes B. Sex, lies and pharmaceuticals. How drug companies plan to profit from female sexual dysfunction. Vancouver: Greystone; 2010.

  8. Bramesfeld A, Grobe T, Schwartz FW. Who is treated, and how, for depression? An analysis of statutory health insurance data in Germany. Soc Psychiatry Epidemiol. 2007;42:740-6.

  9. Castiel L, Álvarez-Dardet C. La salud persecutoria. Rev Saúde Pública. 2007;41:461-6.

  10. Alonso-Coello P, García-Franco A, Guyatt G, Moynihan R. Drugs for pre-osteoporosis: prevention or disease mongering? BMJ. 2008;336:126.

  11. Casino G. Osteoporosis, ¿una epidemia inventada? El País. 25 abril 2006. [citado 5 Nov 2014]. Disponible en: http://elpais.com/diario/2006/04/25/salud/1145916001_850215.html

  12. Wolinsky H. Disease mongering and drug marketing. EMBO. 2005;6:612-4.

  13. Llor C. Medicamentos que matan y crimen organizado. Aten Primaria. 2014;46(4):176-8.

  14. Ugalde A, Homedes N. Medicamentos para lucrar. La transformación de la industria farmacéutica. Salud Colectiva (Buenos Aires). 2009 Sept-Dic;5(3):305-22.

  15. Pérez Peña JL. Dos enfoques sobre los medicamentos y la industria farmacéutica. Rev Cubana Salud Pública. 2004 Dic [citado 1 Nov 2014];30(4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 34662004000400007&ln=es




2020     |     www.medigraphic.com